INTRODUCTION
Enteropathic spondyloarthritis (ES) is a seronegative spondyloarthropathy (SpA) characterized by the presence of articular inflammation in patients aff ected by inflammatory bowel diseases (IBDs), such as Crohn's disease (CD) or ulcerative colitis (UC) [1, 2] . Arthritis is the most frequent extraintestinal manifestation in patients with IBDs [1] and it may primarily involve the axial joints, presenting with definite ankylosing spondylitis (AS) and/or isolated sacroiliitis, or peripheral joints and/or periarticular structures, such as tendons and entheses [3] . The articular manifestations significantly affect health related quality of life (HRQoL) of ES patients [4] . Although a link between inflammation of the joints and gut has been demonstrated [5, 6] , only half of ES patients are actually evaluated by a rheumatologist for proper diagnosis and, thus, for an integrated therapeutic approach through a coordinated action with the treating gastroenterologist [7] . Thus, an inte grated clinical evaluation and therapeutic approach encompassing both the intestinal and articular features in ES patients, will likely be beneficial, particularly for the clinical outcomes. It has been demonstrated by recent studies that tumor necrosis factor (TNF)alpha inhibitors could be effective therapeutic agents against ES [8] , but few to date have reported on their reallife efficacy in this disease.
Herein, we have investigated the role of a gastro rheumatologic multidisciplinary management and therapeutic approach in ES patients through evaluation of the efficacy of the TNF-alpha inhibitor adalimumab (Ada), assessing the efficacy on both gastrointestinal and rheumatologic disease activities and on the patientreported HRQoL.
MATERIALS AND METHODS

Patients and study design
This study was carried out in a cohort of 52 patients with ES, including 31 affected by CD (59.6%) and 21 by UC (40.3%), collectively representing 23.6% of the 220 overall patient population with IBD in the Spondyloarthritis in IBD Project (commonly referred to as SPIB), described elsewhere [9] . The patients' clinical and laboratory data are shown in Table 1 , and the patient group is henceforth defined as the "ESAN" cohort (Enteropathic spondyloarthritis from Ancona, Italy).
At each clinical observation, both the rheumat ologist and the gastroenterologist collaborated in a shared session to develop the therapeutic strategy by applying a specifically designed algorithm ( Figure 1 ) that was mainly based upon gastrointestinalarticular disease activity and the site of articular involvement at diagnosis (axial or peripheral arthritis). Briefly, the ES-AN patients were primarily separated into the following two groups for comparative analysis:
Group I (biological drugs-naïve group): This group encompassed three treatment subgroups. In the axialESAN (AxESAN) subgroup, patients were administered Ada as firstline therapy, due to the absolute contraindication for a longcourse treatment with nonsteroidal antiinflammatory drugs (NSAIDs)
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Study measures and evaluation
All patients of the ESAN cohort were assessed for clinical disease activity and HRQoL (Table 2) . Briefly, articular (SpA) disease activity was assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [10] and the Ankylosing Spondylitis Disease Activity ScoreCReactive Protein (ASDASCRP) calculation [11] ; gastrointestinal (IBD) disease activity was assessed with the Crohn's Disease Activity Index (CDAI) for CD [12] and the partial Mayo (pMAYO) score for UC [13] . Patientreported outcomes (PROs) were assessed with tests specific for articularrelated symptoms [i.e. the Bath Ankylosing Spondylitis Functional Index (BASFI)] [14] and gastrointestinalrelated symptoms [i.e. the Inflammatory Bowel Disease Questionnaire (IBDQ)] [15] . Global wellness was assessed by use of the Health Assessment Questionnaire (HAQ), Patient Global Assessment (PtGA), and the Short Form36 health survey (SF36) [16] .
Statistical analysis
Endpoints of this study were the disease activity indexes at baseline and at 6mo and 12mo follow ups. Variables are presented as mean ± standard deviation. Comparisons between groups at baseline in case of IBD. In the peripheralESAN (PerESAN) subgroup, patients with active IBD or who were non responders to a short course of corticosteroids (not more than 3 mo) or NSAIDs (not more than 2 wk) were administered either a diseasemodifying anti rheumatic drug (DMARD), such as either methotrexate (MTX) or sulfasalazine (SSZ), or Ada if erythrocyte sedimentation rate (ESR) was > 30 mm/h and/or Creactive protein (CRP) concentration was > 0.5 mg/dL and/or in the presence of polyarticular inflammatory involvement. In the PerESAN in inactive IBDs subgroup, patients were administered steroids or DMARDs, depending on count number of inflamed joints and systemic inflammation (evaluated by ESR and/or CRP).
Group II (TNF inhibitor-treated group):
This group also encompassed three treatment subgroups. For the first, the Per-ES-AN consisting of patients with still active IBD were switched to another TNFinhibitor (Ada). For the second, the PerESAN consisting of patients with IBD in remission were administered a DMARD in addition to the TNFinhibitor already in use. For the third, the AxESAN patients were switched to Ada, regardless of IBD activity.
In all patients, the TNFinhibitor Ada was used as recommended for IBD treatment: 160 mg in the first week, 80 mg for the next 2 wk, and thereafter 40 mg and between baseline and subsequent assessments were performed, respectively, with unpaired and paired Student's ttests. Correlations between variables were assessed using Pearson's correlation coefficient. Data were analyzed using the SPSS software (v22.0; IBM SPSS Statistics for Windows, Armonk, NY, United States).
RESULTS
Baseline assessment of the patients
In the ESAN cohort, 29 (57.6%) patients were affected by predominant axial SpA (AxESAN) and 23 (42.3%) by peripheral SpA (PerESAN) ( Table 1) . Only 5 patients showed positivity for human leukocyte antigenB27 (9.6%), including 4 affected by AxES AN and 1 by PerESAN. Sacroiliitis was found in all the Ax-ES-AN patients, but 17 (55%) patients fulfilled the Modified New York Criteria for AS, whereas 13 (45%) were affected by nonradiographic axialSpA [2] . Syndesmophytosis was found in 8 (27.6%) of the Ax ESAN patients at different levels, but only 2 (6.9%) presented a bamboo spine radiologic feature at baseline. Concurrent peripheral arthritis and enthesitis were present in about half of the AxESAN patients (44.8%).
According to the established criteria, IBD was active in 63.2% of the CD patients and in 98% of the UC patients, although the degrees of activity varied. At baseline, no differences were observed between the axial and peripheral spondyloarthritis patients and between the CD and UC patients for the articular disease activity (BASDAI, ASDASCRP) and the PROs [IBDQ, BASFI, PtGA, HAQ, SF36 Physical Component Score (PCS) and Mental Component Score (MCS)] (data not shown). Following findings from the integrated evaluation and according to the algorithm presented in Figure 1 , the criteria employed in our study to guide the therapeutic choice were (1) the presence and/or absence of active IBD (evaluated by both the gastroenterologist and by the results of the gastrointestinal tests and PROs); and (2) the site of articular involvement (axial or peripheral joints). Thus, Ada was assigned to a cohort of 30 patients, henceforth defined as the ES-AN/Ada cohort. Among this cohort, 4 were switched from infliximab for inefficacy, and the total was comprised of 20 patients with AxESAN and 10 patients with PerESAN ( Table 1) .
Evaluation of articular and gastrointestinal disease activity
In most of the ESAN/Ada patients, articular disease activity, as assessed by ASDASCRP and BASDAI, was significantly improved at 6mo compared to baseline 
Items and interpretation
Bath Ankylosing Spondylitis Disease Index [10] 6 items: (1) fatigue, (2) back pain, (3) peripheral pain/swelling, (4) discomfort at pressure, (5) morning discomfort, and (6) duration of morning stiffness; Range from 0 to 10, with lower number representing less severe disease activity; Score > 4 = active disease. Ankylosing Spondylitis Disease Activity Score-CReactive Protein [11] 5 items: (1) back pain, (2) morning stiffness, (3) patient global, (4) peripheral pain/swelling, and (5) C-reactive protein; Score < 1.3 = inactive disease; Score 1.3 to < 2.1 = moderate activity; Score 2.1 to ≤ 3.5 = high activity; Score > 3.5 = very high activit; Change ≥ 1.1 = clinically important improvement; Change ≥ 2.0 = major improvement. Crohn's Disease Activity Index [12] 8 items: (1) liquid stools, (2) abdominal pain, (3) general well-being, (4) extra-intestinal manifestations (including arthralgia), (5) use of anti-diarrheals, (6) abdominal masses, and (7) hematocrit, 8) weight; Final score is the sum of items, weighted by different factors; Score < 150 = non-active disease; Score > 150 = active disease; Score > 450 = extremely severe disease. Partial MAYO score [13] 3 items: (1) stool frequency, (2) rectal bleeding, and (3) physician global assessment;
Range from 0 to 9; Score < 2 = disease remission; Score 2-4 = mild disease activity; Score 5-7 = moderate disease activity; Score > 7 = severe disease activity. Bath Ankylosing Spondylitis Functional Index [14] 10 questions designed to determine the degree of functional limitation; Final score ranges from 0 to 10, with lower score indicating less functional limitation. Inflammatory Bowel Disease Questionnaire [15] 32 questions divided into 4 subscales: (1) bowel symptoms (10 questions); (2) systemic symptoms, including sleep disorders and fatigue (5 questions); (3) emotional function, such as depression, aggression and irritation (12 questions);
and (4) social function, meaning the ability to participate in social activities and to work (5 questions); The patient is invited to choose from 1 to 7 for every question; Total score ranges from 32 to 224 points, with lower scores reflecting worse quality of life.
Collected on a numeric rating scale ranging from 0 to 10 for the question asking the patient: "Considering all the ways your disease affects you, how much do you think is active today?" Short Form-36 health survey [16] Generic health status instrument with 8 domains: (1) physical function, (2) body pain, (3) role limitations-physical, (4) general health, (5) vitality, (6) social function, (7) role limitations-emotional, and (8) mental health; Greater scores reflect better health status; Summarized in two summary scores defined as the (1) (ASDASCRP: 3.2 ± 0.8 vs 1.9 ± 0.6, P < 0.001; BASDAI: 5.5 ± 1.7 vs 3.2 ± 1.8, P < 0.001). A major clinical improvement (ASDAS change of ≥ 2) occurred in 21% and an important clinical improvement (ASDAS change of ≥ 1.1) occurred in 52% (Figure 2A ). The improvement of articular disease was significant in both the axial and the peripheral subgroups of patients (P < 0.001 for both comparisons). The clinical improvement at the articular level was maintained at the 12mo examination (Figure 2A) . Regarding the gastrointestinal disease activity, in the CD patients the treatment led to a fast, consistent and significant improvement of the gastrointestinal symptoms at 6 mo, as assessed by the CDAI score (181.3 ± 93.2 vs 112.3 ± 63.0, P < 0.01; Figure  2A) , and maintained at 12 mo, when the clinical remission was observed in almost all patients ( Figure  2A) . In parallel, a significant clinical improvement was observed also in the UC patients, as shown by the decrease of the pMAYO score at the 6mo and 12mo examinations (Figure 2A ). All the values and comparisons are detailed in Table 3 .
Evaluation of the HRQoL
ES-AN/Ada patients reported significant improvement, from baseline to 6 mo, in the IBDQ (145.3 ± 36.8 vs 172.8 ± 36.7, P < 0.01), PtGA (61.1 ± 20.6 vs 35.6 ± 19.1, P < 0.01; Figure 2B ) and HAQ (4.8 ± 7.9 vs 2.0 ± 4.2, P < 0.05) scores, and this improvement was maintained at 12 mo. Moreover, regarding the PROs impacting articular function and global health wellness, significant improvements were observed from baseline to 6 mo in the BASFI (3.2 ± 2.4 vs 1.8 ± 1.4, P < 0.01), Sf36/PCS (42.2 ± 9.7 vs 48.4 ± 7.3, P < 0.01) and Sf36/MCS scores (35.4 ± 10.9 vs 39.4± 8.8, P < 0.05; Figure 2C) ; again, the improvements were maintained at 12 mo. The improvement of all the scores for PROs was similar in both the AxESAN/Ada and PerESAN/ Ada subgroups at each followup observation. All the values and comparisons are detailed in Table 3 .
Correlations between variables
At baseline, it is noteworthy that a consistent signi ficant correlation was observed between the IBDQ test (specific for the evaluation of the PROs related to the gastrointestinal disease activity) and the clinimetric scores of articular activity, as assessed by ASDASCRP ( Figure 3A) , BASDAI, and with most of the PROs of the HRQoL, as assessed by Sf36/MCS and CDAI (Table  4) . Moreover, articular disease activity at baseline was significantly correlated with worse results in the HRQoL tests, as shown by the Sf36/PCS and Sf36/ MCS scores (Table 4) . After 12 mo of Ada treatment, improvement of the articular activity (ASDASCRP) correlated significantly with decrease in the gastrointestinal disease activity scores, as assessed by CDAI in the CD patients ( Figure 4A ) and IBDQ in all of the patients, and with most of the PROs of the HRQoL, as shown by the Sf36/PCS (r = 0.30, P < 0.05) and Sf36/MCS (r = 0.41, P < 0.01) scores ( Figure 2C ), as well as the BASFI (r = 0.57, P < 0.001), PtGA (r = 0.37, P < 0.01) and HAQ (r = 0.28, P < 0.05) scores. All the correlations for the values at 12mo examination are detailed in Table 4 .
Tolerability
Ada was well tolerated throughout the followup period. Side effects reported included recurrent upper respiratory tract infections (n = 2), bothersome hair loss (n = 1), and widespread itch (n = 2); but none necessitated suspension of the treatment. One patient suffered from a serious infection (axillary suppurative hidradenitis) that required prolonged antibiotic treat ment. The other minor side effects reported were headache and fatigue.
DISCUSSION
The association between SpAs and IBDs has been known since the beginning of the last century [17] .
However, gastroenterologists and rheumatologists continue to carry out their clinical evaluations and the therapeutic management of these diseases, now known collectively as ES, independently. In this regard, the different clinical guidelines employed by the two medical specialists may lead to different therapeutic decisions for the same clinical scenario, ultimately harboring potential for different clinical outcomes of the disease. A critical issue in the clinical management of ES is the correct therapeutic choice, and an im portant role has emerged recently for the TNFalpha inhibitors in this regard. Infliximab was the first TNFalpha inhibitor used in ES [18] , but Ada has recently been applied to ES patients affected by CD and has achieved rates of clinical remission up to 50% [19] . To our knowledge, this is the first study demon strating the efficacy of the integrated gastrorhe umatologic approach for evaluation and therapeutic management of ES patients, with efficacy evidenced through assessments of disease activity and HRQoL over a 12mo period. As dictated by our operative algorithm, both the gastroenterologist and the rheumatologist evaluated each of the patients in the study cohort, with both of the specialists collaborating to choose the optimal therapy. This integrated multidisciplinary approach, therefore, considered the gastrointestinal and articular disease activities simultaneously and, most importantly in the latter case, the site of articular inflammation (axial or peripheral). Thus, for example, in the case of axial spondyloarthritis, the therapy with antiTNFalpha inhibitors was mandatory, following the latest rheumatologic indications [20] . Since only few studies in the literature have so far evaluated the efficacy and safety of antiTNF alpha in ES, we employed the up and coming Ada treatment in our study. The results indicated that in ES patients, regardless of IBD type and/or site of articular involvement, Ada significantly improves the inflammation states of both the joints (assessed by ASDASCRP and BASDAI) and gut (assessed by CDAI or pMAYO score), as well as the HRQoL. Moreover, the benefits were already observable at 6 mo and the improvements were maintained at 12 mo. Ada also consistently improved not only the physical function in almost all ES patients (assessed by PtGA, BASFI, HAQ and Sf36/PCS) but also their psychological function (assessed by Sf36/MCS and IBDQ), from baseline to 6 mo.
It is noteworthy that in our study the strong linear relationship between articulargastrointestinal disease activity and the PROs confirms the strong link between gut and joint inflammations. In fact, the IBDQ (specific for the gastrointestinalrelated quality of life) strongly correlated with results of the clinimetric tests of articular activity (ASDASCRP, BASDAI and BASFI); additionally, the articular disease activity (assessed by ASDASCRP) strongly correlated with all of the PROs studied, even those specific for IBDs. To the contrary, however, at baseline the gastrointestinal disease activity scores (except for those of the IBDQ) did not correlate well with the other variables, but at 12 mo of therapy the CDAI correlated with most of the articular and PROs of HRQoL. This latter finding may be consequent to the different degrees of disease activities reported by the patients at baseline, which, after the treatment, tend to be globally ameliorated both at the gastrointestinal and articular levels. Thus, since only the ASDASCRP test proved to be the most reliable in all patients in our study, we think that it should be necessary to develop composite scores and HRQoL questionnaires specific and suitable for ES patients at diagnosis, similar to those developed for other multidisciplinary diseases, such as psoriatic arthritis [21] . In conclusion, in our work that was carried out in a reallife cohort of a significant number of ES patients, we demonstrated that Ada produced a fast and significant improvement of both the gas trointestinal and articular scores of disease activity and, moreover, of the HRQoL. This clinical result was achieved by employing an integrated outpatient clinic specific for ES patients, as recently endorsed, particularly with regard to early diagnosis [22, 23] . The integrated approach provided the optimal management of both the multidisciplinary clinical evaluation and the therapy of these patients. Further studies are certainly warranted to assess the longterm outcomes, and tolerability, of Ada and other TNFalpha inhibitors in patients affected by ES.
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Enteropathic spondyloarthritis (ES) is characterized by articular inflammation in patients with inflammatory bowel diseases (IBDs), such as Crohn's disease or ulcerative colitis. Arthritis is the most frequent extra-intestinal manifestation found in IBD patients, yet only half of the ES patients are actually evaluated by a rheumatologist for a proper diagnosis and, thereafter, for receipt of an integrated therapeutic approach through a coordinated action between the two specialists.
Research frontiers
Considering the multidisciplinary intrinsic "face" of IBDs and the novel therapeutic opportunities that comprise the biological drugs, as in the case of anti-tumor necrosis factor (TNF)-alpha inhibitors, an integrated approach and evaluation of all ES patients should be routinely employed and strongly encouraged to obtain the best therapeutic efficacy on all the clinical manifestations of this disease.
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In this work, the authors have demonstrated that the integrated (simultaneous) evaluation of patients affected by ES, through the coordinated efforts of a gastroenterologist and rheumatologist, led to the best therapeutic approach, thereby allowing the patients to achieve a consistent clinical remission of both the articular and gastrointestinal inflammations.
Applications
Through this study authors have been able to generate a simple working flowchart of the multidisciplinary clinical care process applied during the patients' integrated assessment. They suggest that in patients with ES and in consideration of the therapeutic choice, particular attention should be paid to the presence of active intestinal disease, presence of active articular (arthritis) and/or periarticular (enthesitis) disease and localization of the joints' inflammation (peripheral or axial, as in the case of sacroiliitis).
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ES belongs to the group of seronegative spondyloarthritis (SpA) and, as such, is characterized by the presence of arthritis in patients affected by IBDs; it is also known as SpA-IBD.
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